283 related articles for article (PubMed ID: 8015085)
1. Immunohistochemical expression of P53 tumor suppressor gene protein in adult germ cell testis tumors: clinical correlation in stage I disease.
Lewis DJ; Sesterhenn IA; McCarthy WF; Moul JW
J Urol; 1994 Aug; 152(2 Pt 1):418-23. PubMed ID: 8015085
[TBL] [Abstract][Full Text] [Related]
2. Proliferating cell nuclear antigen expression to predict occult disease in clinical stage I nonseminomatous testicular germ cell tumors.
Fernandez EB; Sesterhenn IA; McCarthy WF; Mostofi FK; Moul JW
J Urol; 1994 Oct; 152(4):1133-8. PubMed ID: 7915335
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical expression of Ki-67 to predict lymph node involvement in clinical stage I nonseminomatous germ cell tumors.
Heidenreich A; Schenkmann NS; Sesterhenn IA; Mostofi FK; McCarthy WF; Heidenreich B; Moul JW
J Urol; 1997 Aug; 158(2):620-5. PubMed ID: 9224380
[TBL] [Abstract][Full Text] [Related]
4. Cluster analysis of p53 and Ki67 expression, apoptosis, alpha-fetoprotein, and human chorionic gonadotrophin indicates a favorable prognostic subgroup within the embryonal carcinoma germ cell tumor.
Mazumdar M; Bacik J; Tickoo SK; Dobrzynski D; Donadio A; Bajorin D; Motzer R; Reuter V; Bosl GJ
J Clin Oncol; 2003 Jul; 21(14):2679-88. PubMed ID: 12860944
[TBL] [Abstract][Full Text] [Related]
5. Flow cytometric and quantitative histological parameters to predict occult disease in clinical stage I nonseminomatous testicular germ cell tumors.
Moul JW; Foley JP; Hitchcock CL; McCarthy WF; Sesterhenn IA; Becker RL; Griffin JL
J Urol; 1993 Sep; 150(3):879-83. PubMed ID: 8393944
[TBL] [Abstract][Full Text] [Related]
6. Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis.
Heidenreich A; Sesterhenn IA; Mostofi FK; Moul JW
Cancer; 1998 Sep; 83(5):1002-11. PubMed ID: 9731905
[TBL] [Abstract][Full Text] [Related]
7. Percentage of embryonal carcinoma and of vascular invasion predicts pathological stage in clinical stage I nonseminomatous testicular cancer.
Moul JW; McCarthy WF; Fernandez EB; Sesterhenn IA
Cancer Res; 1994 Jan; 54(2):362-4. PubMed ID: 8275469
[TBL] [Abstract][Full Text] [Related]
8. [Correlation between p-53 expression and clinical resistance in testicular cancer].
Hanna E; Bodrogi I; Institoris E; Bak M
Orv Hetil; 1996 Jan; 137(2):59-64. PubMed ID: 8721869
[TBL] [Abstract][Full Text] [Related]
9. Increased p53 protein does not correlate to p53 gene mutations in microdissected human testicular germ cell tumors.
Schenkman NS; Sesterhenn IA; Washington L; Tong YA; Weghorst CM; Buzard GS; Srivastava S; Moul JW
J Urol; 1995 Aug; 154(2 Pt 1):617-21. PubMed ID: 7609148
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemistry expression of P53, Ki67, CD30, and CD117 and presence of clinical metastasis at diagnosis of testicular seminoma.
Gallegos I; Valdevenito JP; Miranda R; Fernandez C
Appl Immunohistochem Mol Morphol; 2011 Mar; 19(2):147-52. PubMed ID: 20881837
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical assessment of tumor proliferation and volume of embryonal carcinoma identify patients with clinical stage A nonseminomatous testicular germ cell tumor at low risk for occult metastasis.
Albers P; Miller GA; Orazi A; Ulbright TM; Albers J; Donohue JP; Foster RS
Cancer; 1995 Feb; 75(3):844-50. PubMed ID: 7828136
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of immunohistochemical proliferation markers (Ki-67/MIB-1 and proliferation-associated nuclear antigen), p53 protein accumulation, and neovascularization in clinical stage A nonseminomatous testicular germ cell tumors.
Albers P; Orazi A; Ulbright TM; Miller GA; Haidar JH; Donohue JP; Foster RS
Mod Pathol; 1995 Jun; 8(5):492-7. PubMed ID: 7545814
[TBL] [Abstract][Full Text] [Related]
13. MIB-1 immunohistochemistry in clinical stage I nonseminomatous testicular germ cell tumors predicts patients at low risk for metastasis.
Albers P; Bierhoff E; Neu D; Fimmers R; Wernert N; Müller SC
Cancer; 1997 May; 79(9):1710-6. PubMed ID: 9128986
[TBL] [Abstract][Full Text] [Related]
14. Tumor proliferative activity is predictive of pathological stage in clinical stage A nonseminomatous testicular germ cell tumors.
Albers P; Ulbright TM; Albers J; Miller GA; Orazi A; Crabtree WN; Baniel J; Reister T; Sidner RA; Foster RS; Donohue JP
J Urol; 1996 Feb; 155(2):579-86. PubMed ID: 8558664
[TBL] [Abstract][Full Text] [Related]
15. Estrogen receptor-beta expression in human testicular germ cell tumors.
Pais V; Leav I; Lau KM; Jiang Z; Ho SM
Clin Cancer Res; 2003 Oct; 9(12):4475-82. PubMed ID: 14555521
[TBL] [Abstract][Full Text] [Related]
16. Transition from in situ to invasive testicular germ cell neoplasia is associated with the loss of p21 and gain of mdm-2 expression.
Datta MW; Macri E; Signoretti S; Renshaw AA; Loda M
Mod Pathol; 2001 May; 14(5):437-42. PubMed ID: 11353054
[TBL] [Abstract][Full Text] [Related]
17. Alterations of the p53 tumor suppressor gene in carcinoma in situ of the testis.
Kuczyk MA; Serth J; Bokemeyer C; Jonassen J; Machtens S; Werner M; Jonas U
Cancer; 1996 Nov; 78(9):1958-66. PubMed ID: 8909317
[TBL] [Abstract][Full Text] [Related]
18. Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues.
Ulbright TM
Mod Pathol; 2005 Feb; 18 Suppl 2():S61-79. PubMed ID: 15761467
[TBL] [Abstract][Full Text] [Related]
19. OCT4 staining in testicular tumors: a sensitive and specific marker for seminoma and embryonal carcinoma.
Jones TD; Ulbright TM; Eble JN; Baldridge LA; Cheng L
Am J Surg Pathol; 2004 Jul; 28(7):935-40. PubMed ID: 15223965
[TBL] [Abstract][Full Text] [Related]
20. [Expression and diagnostic significance of OCT4, CD117 and CD30 in germ cell tumors].
Teng LH; Lu DH; Xu QZ; Fu YJ; Yang H; He ZL
Zhonghua Bing Li Xue Za Zhi; 2005 Nov; 34(11):711-5. PubMed ID: 16536313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
